Drug Profile
Research programme: nucleic acid therapeutics - Adhera Therapeutics
Alternative Names: Duchenne muscular dystrophy therapeutics - Adhera Therapeutics; Myotnoic dystrophy therapeutics - Adhera Therapeutics; Rare disease therapeutics - Adhera TherapeuticsLatest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator Marina Biotech
- Developer Adhera Therapeutics
- Class Antisense RNA; MicroRNAs; Nucleic acids
- Mechanism of Action Nucleic acid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy; Myotonic dystrophy
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA
- 28 Mar 2020 No recent reports of development identified for preclinical development in Myotonic dystrophy in USA
- 02 May 2016 Microlin Bio terminates its plans to acquire nucleic acid therapeutics assets